Palantir Posts 85% Revenue Growth but Faces Scaling and Contract Hurdles
Palantir reported 85% year-over-year revenue growth yet shares are down 25% following investor concerns over scaling its elite deployment model. Management admits U.S. demand outpaces its 70-person sales team, while NHS contract review and a 43.7% net margin at 49.2x price-to-sales heightens re-rating risk.
1. Paradox of Growth and Stock Performance
Palantir delivered 85% year-over-year revenue growth but its stock has declined 25% as investors question whether its specialized deployment model can keep up with opportunity. Its price-to-sales multiple stands at 49.2x, leaving little room for disappointment.
2. Salesforce Constraints and Scaling Risks
Management acknowledges U.S. demand outpaces the company's 70-person salesforce, underscoring a bottleneck in its elite, technical deployment teams. Without rapid hiring and training of specialized staff, the 67.7% revenue growth rate may face forced deceleration.
3. Government Contract Review and Margin Pressure
A full review of its NHS contract in the U.K. adds political risk to major client concentration, while peak net margin of 43.7% could reverse if growth stalls and the company invests in expansion or price competition. Reversion to historical averages would pressure earnings.
